Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide
Clinical & Translational Immunology · 2026-05 · 15 (5)
DOI: 10.1002/cti2.70098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 05.05.2026. Verfasst von Lachlan J Dobson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology University of Otago Dunedin New Zealand. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand.
Abstract (Originalsprache)
Objectives
The anti‐PD‐L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD‐1/L1 immune checkpoint, while inducing antibody‐dependent cellular cytotoxicity (ADCC) from CD16a + NK cells. However, subsets of patients possess lower‐affinity CD16a allotypes that limit ADCC capacity of monoclonal antibodies. In this study, we modified the Fc domain of avelumab with characterised mutations to enhance ADCC across all CD16a allotypes.
Methods
Comparisons between the wild‐type avelumab and modified ‘AveFc5M’ were carried out to assess the impacts of introduced mutations on PD‐L1 blockade, ADCC induction and complement‐dependent cytotoxicity (CDC) induction. To assess ADCC, a range of PD‐L1 + target cells were coated with mab prior to incubation with effector cells, with both high‐ and low‐affinity CD16a allotypes represented. Human serum was employed for assessing CDC.
Results
Both antibodies exhibited equivalent PD‐L1 blocking activity. Notably, the modified AveFc5M displayed significantly enhanced ADCC across diverse tumor cell–effector cell combinations. Fc mutations also conferred the ability to mediate complement‐dependent cytotoxicity (CDC) against a PD‐L1 + lymphoma cell line. However, short term activation of NK cells or long‐term expansion on artificial antigen presenting cells, led to upregulation of PD‐L1 on NK cells. Addition of avelumab or AveFc5M to these NK cell populations induced a marked reduction in viable NK cells via ADCC‐mediated fratricide.
Conclusion
These findings demonstrate that Fc engineering of avelumab can substantially augment ADCC and CDC activity against PD‐L1 + tumors. However, the enhanced effector function of AveFc5M led to NK cell fratricide, potentially limiting NK cell‐dominated anti‐cancer responses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology University of Otago Dunedin New Zealand.
- Haematology Research Group, Department of Pathology and Biomedical Science University of Otago Christchurch New Zealand.
- Haematology Department Christchurch Hospital Christchurch New Zealand.
- Department of Histology, Faculty of Medicine University of Indonesia Jakarta Indonesia.
ORCID-Profile: Lachlan J Dobson, Alexander D McLellan
Förderung
- Health Research Council of New Zealand
Zitieren
APA
Dobson, L. J., Hock, B. D., Drabble, A. H., Goddard, L., McKenzie, J. L., MacPherson, S. A., & McLellan, A. D. (2026). Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology, 15(5). https://doi.org/10.1002/cti2.70098
Vancouver
Dobson LJ, Hock BD, Drabble AH, Goddard L, McKenzie JL, MacPherson SA, et al. Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology. 2026;15(5). doi:10.1002/cti2.70098
BibTeX
@article{Dobson2026,
author = {Dobson, Lachlan J and Hock, Barry D and Drabble, Ariana Ht and Goddard, Liping and McKenzie, Judith L and MacPherson, Sean A and McLellan, Alexander D},
title = {Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide},
journal = {Clinical & Translational Immunology},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cti2.70098}
}
EUVIMED